Pharmaceutical News

RSS

FDA grants Fast Track Designation for Emergent BioSolutions' NuThrax vaccine

Emergent BioSolutions Inc. announced today that its investigational anthrax vaccine, NuThrax, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA).

10 Jun 2011

Drugs for enlarged prostate raise cancer risk

According to health officials, this Thursday, a class of drugs meant to improve symptoms of an enlarged prostate gland may actually increase the chance of getting a more serious form of prostate cancer. However they also said the drugs' benefits outweigh the risks.

9 Jun 2011

New vaccines on the horizon

In a report published in The Lancet, researchers say there is the potential to develop 20 new or improved vaccines over the next decade. They emphasize that funding is crucial - but so is trust and confidence in vaccines. It is said that AIDS and malaria vaccines as the most important areas for research. Authors further suggest that neglected tropical diseases, such as leprosy, should also be investigated.

9 Jun 2011

Respira introduces breakthrough Dry Powder Inhaler

Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, introduces the company's Dry Powder Inhaler (DPI) as a breakthrough solution for the pharmaceutical industry. Based on proprietary drug engine technology (DET), Respira Therapeutics' DPI significantly improves therapeutic performance and enables addressing the unmet medical needs of patients with severe respiratory diseases.

9 Jun 2011

New vaccine leads to dramatic fall in meningitis A cases

Burkina Faso, Mali, and Niger report the lowest number of confirmed meningitis A cases ever recorded during an epidemic season this year following the successful introduction of a new vaccine that could eliminate the primary cause of the deadly disease from Africa's meningitis belt, announced the Meningitis Vaccine Project (MVP) today, which spearheaded development of the vaccine.

9 Jun 2011

University of Mississippi grants ChromaDex global rights to pterostilbene

ChromaDex Corp. and the University of Mississippi today announced the university has granted the natural products company the exclusive worldwide patent rights to a potential new therapeutic use for pterostilbene (tero-STILL-bean) as an anxiolytic or anti-anxiety agent. ChromaDex' pTeroPure® is an ultra-pure formulation of pterostilbene, a compound found in blueberries and demonstrated to have multiple health benefits.

9 Jun 2011

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck, known as MSD outside the United States and Canada, today announced changes to the prescribing information in the United States for the highest dose of simvastatin, 80 mg, and the use of simvastatin with certain other medicines.

9 Jun 2011

JDRF, Selecta Biosciences partner to develop type 1 diabetes vaccine

The Juvenile Diabetes Research Foundation (JDRF) and Selecta Biosciences, Inc. announced today that they have established a research collaboration to support Selecta's development of a vaccine technology, which may subsequently help to better treat and potentially prevent type 1 diabetes.

9 Jun 2011

Ameritox launches Rx Guardian CD, next-generation pain-medication monitoring solution

Ameritox, the leader in pain-medication monitoring, today announced the launch of Rx Guardian CD, its next-generation pain-medication monitoring solution and part of the patented Rx Guardian process.

9 Jun 2011

U.S. FDA announces safety label changes for cholesterol-lowering medication, simvastatin

The U.S. Food and Drug Administration today is announcing safety label changes for the cholesterol-lowering medication simvastatin because the highest approved dose--80 milligram (mg)--has been associated with an elevated risk of muscle injury or myopathy, particularly during the first 12 months of use.

9 Jun 2011

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that Seattle Genetics has exercised an option to co-develop a second antibody-drug conjugate (ADC) under the companies' existing ADC collaboration agreement.

9 Jun 2011

IPS examines negotiations over intellectual property laws affecting generic AIDS drugs

Inter Press Service examines how "moves by developed nations such as the United States to tighten intellectual property laws are threatening to limit production and distribution of generic drugs, which experts say have been and will remain key in the prevention and treatment of HIV/AIDS and currently account for 80 percent of HIV/AIDS treatment."

9 Jun 2011

Paladin to commercialize Silenor for treatment of insomnia in Canada, South America and Africa

Somaxon Pharmaceuticals, Inc. and Paladin Labs Inc. today announced that they have entered into an exclusive collaboration under which Paladin will commercialize Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance in Canada, South America and Africa.

8 Jun 2011

Therapeutic equivalent to replace penicillin

Antibiotics are among the greatest achievements of medical science. But lately the former multi-purpose weapon fails in the battle against infectious diseases. Bacteria are increasingly developing resistance to antibiotics. Researchers have now found a therapeutic equivalent which could replace penicillin and related phamaceuticals.

8 Jun 2011

Adoption of premium-priced sclerotherapy agents will contribute to growth of US sclerotherapy market

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the United States sclerotherapy market will experience rapid procedural growth stemming from favorable patient demographics and increased patient demand. Polidocanol, a sclerosing agent used to chemically treat varicose and spider veins, received FDA approval in 2010 and is expected to show significant growth in the US.

8 Jun 2011

Novation recognizes APP with NOVAPLUS Pharmacy Manufacturer of the Year

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., has been named NOVAPLUS Pharmacy Manufacturer of the Year by Novation, the industry's leading supply contracting company.

8 Jun 2011

GSK, Crucell to test second-generation malaria vaccine

GlaxoSmithKline and drug company Crucell, a division of Johnson & Johnson, will collaborate with the PATH Malaria Vaccine Initiative to test a second-generation malaria vaccine "within the next couple of months," Reuters reports.

8 Jun 2011

GAVI appeals for $3.7B ahead of pledging conference despite lower vaccine prices

The GAVI Alliance has appealed to donors for $3.7 billion to be pledged during an upcoming conference despite announcements by several major pharmaceutical companies to lower the prices of their vaccines for childhood diseases, the Associated Press/Washington Post reports.

8 Jun 2011

OzHealth Pharma, Moberg Derma partner to distribute Emtrix in Australia and New Zealand

Moberg Derma AB has entered into a distribution agreement with OzHealth Pharma for Emtrix - for discolored and damaged nails caused by nail fungus or nail psoriasis.

8 Jun 2011

Bio-Nucleonics resumes production of metastatic cancer drug, Strontium-89

Bio-Nucleonics, Inc., a life sciences Company, specializing in the development and manufacture of radiopharmaceuticals, medical devices and imaging agents, will be attending the Society of Nuclear Medicine (SNM) Annual Meeting, held in San Antonio, TX, June 4th through 8th, 2011.

8 Jun 2011

Pharmaceutical News

FDA grants Fast Track Designation for Emergent BioSolutions' NuThrax vaccine

Drugs for enlarged prostate raise cancer risk

New vaccines on the horizon

Respira introduces breakthrough Dry Powder Inhaler

New vaccine leads to dramatic fall in meningitis A cases

University of Mississippi grants ChromaDex global rights to pterostilbene

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

JDRF, Selecta Biosciences partner to develop type 1 diabetes vaccine

Ameritox launches Rx Guardian CD, next-generation pain-medication monitoring solution

U.S. FDA announces safety label changes for cholesterol-lowering medication, simvastatin

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

IPS examines negotiations over intellectual property laws affecting generic AIDS drugs

Paladin to commercialize Silenor for treatment of insomnia in Canada, South America and Africa

Therapeutic equivalent to replace penicillin

Adoption of premium-priced sclerotherapy agents will contribute to growth of US sclerotherapy market

Novation recognizes APP with NOVAPLUS Pharmacy Manufacturer of the Year

GSK, Crucell to test second-generation malaria vaccine

GAVI appeals for $3.7B ahead of pledging conference despite lower vaccine prices

OzHealth Pharma, Moberg Derma partner to distribute Emtrix in Australia and New Zealand

Bio-Nucleonics resumes production of metastatic cancer drug, Strontium-89

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News